Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

IntelGenx Technologies Corp. IGXT OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
21/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

IntelGenx Technologies Corp. (IGXT) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.

IGXT Analyst Ratings

Buy
2
Ratings
2 Buy
Based on 2 analysts giving stock ratings to IntelGenx Technologies Corp. in the past 3 months
Rating breakdown
Buy
2 100%
100%
Buy
2 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

ASCLF
ASCLF
Ascletis Pharma Inc.
$2.10
+0.00%
 NUVB
NUVB
Nuvation Bio Inc.
$4.82
-0.72%
 ETON
ETON
Eton Pharmaceuticals, Inc.
$26.97
-0.55%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.91
-0.02%
 CADL
CADL
Candel Therapeutics, Inc.
$5.15
+0.98%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.30
+3.13%
 FENC
FENC
Fennec Pharmaceuticals Inc.
$6.50
+4.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message